Free Trial

Bicara Therapeutics (BCAX) Stock Price, News & Analysis

Bicara Therapeutics logo
$10.70 -0.49 (-4.38%)
Closing price 04:00 PM Eastern
Extended Trading
$10.72 +0.02 (+0.19%)
As of 05:33 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

About Bicara Therapeutics Stock (NASDAQ:BCAX)

Advanced

Key Stats

Today's Range
$10.60
$11.08
50-Day Range
$9.99
$12.46
52-Week Range
$7.80
$28.09
Volume
368,754 shs
Average Volume
334,774 shs
Market Capitalization
$583.79 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$32.25
Consensus Rating
Buy

Company Overview

Bicara Therapeutics Stock Analysis - MarketRank™

See Top-Rated MarketRank™ Stocks
42nd Percentile Overall Score

BCAX MarketRank™: 

Bicara Therapeutics scored higher than 42% of companies evaluated by MarketBeat, and ranked 641st out of 953 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    Bicara Therapeutics has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 8 buy ratings, 1 hold rating, and no sell ratings.

  • Upside Potential

    Bicara Therapeutics has a consensus price target of $32.25, representing about 201.4% upside from its current price of $10.70.

  • Amount of Analyst Coverage

    Bicara Therapeutics has only been the subject of 3 research reports in the past 90 days.

  • Read more about Bicara Therapeutics' stock forecast and price target.
  • Earnings Growth

    Earnings for Bicara Therapeutics are expected to grow in the coming year, from ($2.59) to ($1.74) per share.

  • Price to Book Value per Share Ratio

    Bicara Therapeutics has a P/B Ratio of 1.18. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

  • Read more about Bicara Therapeutics' valuation and earnings.
  • Percentage of Shares Shorted

    17.46% of the float of Bicara Therapeutics has been sold short.
  • Short Interest Ratio / Days to Cover

    Bicara Therapeutics has a short interest ratio ("days to cover") of 12.3, which indicates bearish sentiment.
  • Change versus previous month

  • Dividend Yield

    Bicara Therapeutics does not currently pay a dividend.

  • Dividend Growth

    Bicara Therapeutics does not have a long track record of dividend growth.

  • Percentage of Shares Shorted

    17.46% of the float of Bicara Therapeutics has been sold short.
  • Short Interest Ratio / Days to Cover

    Bicara Therapeutics has a short interest ratio ("days to cover") of 12.3, which indicates bearish sentiment.
  • Change versus previous month

  • News Sentiment

    Bicara Therapeutics has a news sentiment score of 1.31. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 1.02 average news sentiment score of Medical companies.
  • News Coverage This Week

    MarketBeat has tracked 4 news articles for Bicara Therapeutics this week, compared to 4 articles on an average week.
  • Search Interest

    7 people have searched for BCAX on MarketBeat in the last 30 days.
  • MarketBeat Follows

    1 people have added Bicara Therapeutics to their MarketBeat watchlist in the last 30 days.
  • Insider Buying vs. Insider Selling

    In the past three months, Bicara Therapeutics insiders have not sold or bought any company stock.

  • Percentage Held by Insiders

    15.50% of the stock of Bicara Therapeutics is held by insiders. A high percentage of insider ownership can be a sign of company health.

  • Read more about Bicara Therapeutics' insider trading history.
Receive BCAX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Bicara Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

BCAX Stock News Headlines

What The Silver Boom Could Mean For You…
AI, electric vehicles, and even global central banks are quietly fueling record demand for silver. This once-overlooked metal isn’t just about “green tech” anymore — it’s becoming critical to the AI revolution and modern energy systems. A new report explains why silver may be one of the most undervalued assets in the market today, and how everyday investors can use it to diversify and protect their savings. It also outlines a simple IRS-approved strategy that makes owning silver easier than most people realize.tc pixel
See More Headlines

BCAX Stock Analysis - Frequently Asked Questions

Bicara Therapeutics' stock was trading at $17.42 at the beginning of 2025. Since then, BCAX shares have decreased by 38.6% and is now trading at $10.70.

Bicara Therapeutics Inc. (NASDAQ:BCAX) issued its quarterly earnings results on Tuesday, August, 12th. The company reported ($0.50) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.54) by $0.04.

Bicara Therapeutics (BCAX) raised $315 million in an initial public offering (IPO) on Friday, September 13th 2024. The company issued 17,500,000 shares at $18.00 per share.

Bicara Therapeutics' top institutional shareholders include Vestal Point Capital LP (9.16%), Geode Capital Management LLC (1.23%), Bank of America Corp DE (0.83%) and Schroder Investment Management Group (0.78%).
View institutional ownership trends
.

Shares of BCAX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Company Calendar

Last Earnings
8/12/2025
Today
9/25/2025
Next Earnings (Estimated)
11/11/2025
Fiscal Year End
12/31/2025

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Sector
Medical
Industry
MED - BIOMED/GENE
Sub-Industry
Pharmaceutical Products
Current Symbol
NASDAQ:BCAX
Previous Symbol
NASDAQ:BCAX
CIK
2023658
Fax
N/A
Employees
32
Year Founded
N/A

Price Target and Rating

High Price Target
$48.00
Low Price Target
$8.00
Potential Upside/Downside
+198.9%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
10 Analysts

Profitability

EPS (Trailing Twelve Months)
($3.17)
Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
-$68 million
Net Margins
N/A
Pretax Margin
N/A
Return on Equity
-21.67%
Return on Assets
-20.89%

Debt

Debt-to-Equity Ratio
N/A
Current Ratio
25.80
Quick Ratio
25.80

Sales & Book Value

Annual Sales
N/A
Price / Sales
N/A
Cash Flow
N/A
Price / Cash Flow
N/A
Book Value
$9.04 per share
Price / Book
1.19

Miscellaneous

Outstanding Shares
54,563,000
Free Float
46,106,000
Market Cap
$588.73 million
Optionable
N/A
Beta
N/A

Social Links

7 Stocks That Could Be Bigger Than Tesla, Nvidia, and Google Cover

Looking for the next FAANG stock before everyone has heard about it? Enter your email address to see which stocks MarketBeat analysts think might become the next trillion dollar tech company.

Get This Free Report

This page (NASDAQ:BCAX) was last updated on 9/25/2025 by MarketBeat.com Staff
From Our Partners